Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach
暂无分享,去创建一个
Seth Falcon | Ruth Etzioni | Roman Gulati | S. Falcon | Ruth Etzioni | D. Penson | R. Gulati | David F Penson
[1] A Tsodikov,et al. A population model of prostate cancer incidence , 2006, Statistics in medicine.
[2] Lurdes Y T Inoue,et al. Combining longitudinal studies of PSA. , 2004, Biostatistics.
[3] J. Donovan,et al. Does current evidence justify prostate cancer screening in Europe? , 2005, Nature Clinical Practice Oncology.
[4] E. Feuer,et al. Asymptomatic incidence and duration of prostate cancer. , 1998, American journal of epidemiology.
[5] M. Cowen,et al. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. , 1999, The Journal of urology.
[6] M. Cowen,et al. A Markov model of the natural history of prostate cancer. , 1994, Journal of clinical epidemiology.
[7] E. Feuer,et al. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates , 2002, Cancer.
[8] Ruth Etzioni,et al. Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends , 2008, Biometrics.
[9] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[10] Michael J Barry,et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut , 2002, BMJ : British Medical Journal.
[11] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[12] D. Johnston,et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. , 2000, The Journal of urology.
[13] M. Stampfer,et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.
[14] Barnett S Kramer,et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. , 2005, The Journal of urology.
[15] C G Chute,et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.
[16] M. Barry. Revisiting my personal decision about prostate‐specific antigen testing in 2005 , 2005, BJU international.
[17] E. Feuer,et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. , 2004, American journal of epidemiology.
[18] P. Albertsen. What is the value of screening for prostate cancer in the US? , 2005, Nature Clinical Practice Oncology.
[19] Ruth Etzioni,et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. , 2005, The Journal of urology.
[20] E. Feuer,et al. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.
[21] Peter Müller,et al. Modeling Disease Progression With Longitudinal Markers , 2008, Journal of the American Statistical Association.
[22] E. Feuer,et al. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey , 2007, Cancer.
[23] K. Shinohara,et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. , 2000, The Journal of urology.
[24] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.